Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 9/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866189 | 0.71 | ABCC2 (0.40) | — | |
| SCHEMBL4878338 | 0.71 | SMN1; SMN2 (0.47) | ADORA3TSHRKDM4EALDH1A1OPRM1 | |
| SCHEMBL15575058 | 0.67 | TNKS (0.56) | PLATPGRALDH1A1OPRM1 | |
| Bromide SCHEMBL8857833 | 0.67 | PDE7A (0.40) | JAK2JAK3TSHRKDM4EALDH1A1 | |
| SCHEMBL4647520 | 0.65 | PGR (0.46) | PGROPRM1 | |
| Hydrochloric Acid SCHEMBL16876892 | 0.64 | JAK2 (0.44) | JAK2JAK3PGROPRM1 | |
| SCHEMBL24700883 | 0.64 | JAK2 (0.37) | ADORA3ADORA2BJAK2JAK3TSHR | |
| Bromide SCHEMBL8857859 | 0.64 | PARG (0.48) | JAK2JAK3DRD4KDM4EALDH1A1 | |
| SCHEMBL3243793 | 0.64 | HSD11B1 (0.53) | OPRM1 | |
| SCHEMBL24700886 | 0.64 | ADORA2B (0.79) | ADORA3ADORA2BJAK2JAK3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1991545-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | AstraZeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007071965-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | SDHA, QDPR, PNKP | PLAT 2054/4885ADORA3 4442/4885ADORA2B 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.